Drug
Asp546c
Asp546c: highest development phase Phase 1/2, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| ASP546C NCT07488676 | Phase 1/2 | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma |
Latest
No recent events.
Follow Asp546c on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.